Geroscience & senolytics

01Overview and value chain

Markers: [EC: European Innovation Partnership on Active and Healthy Ageing | OECD: bio-pharma | Regulator: FDA (US), EMA (EU), NMPA (CN)]

Geroscience targets the shared molecular and cellular hallmarks of aging that underlie most chronic age-related diseases, rather than treating each disease separately. Its most clinically advanced arm is senolytics — small molecules or biologics that selectively clear senescent “zombie” cells, which stop dividing but resist apoptosis and instead secrete a toxic inflammatory cocktail (the senescence-associated secretory phenotype, or SASP) that drives chronic low-grade inflammation and drags neighboring healthy cells into senescence. Unity Biotechnology’s lead senolytic, UBX1325, a Bcl-xL inhibitor delivered locally into the eye, has produced 36-week clinical results and a publication in NEJM Evidence supporting long-term vision improvement in diabetic macular edema. In a parallel clinical program, Mayo Clinic researchers ran a Phase 1 trial of the senolytic combination dasatinib plus quercetin (D+Q) in diabetic kidney disease, directly measuring a reduction in senescent-cell markers in treated patients. Rubedo Life Sciences has reported positive preliminary Phase 1 results for RLS-1496, a topical GPX4-modulating senolytic for plaque psoriasis, atopic dermatitis and skin aging, identified through its AI-driven ALEMBIC platform. Altos Labs, launched around 2022 with roughly $3 billion in funding, is pursuing a parallel strategy — partial cellular reprogramming to reverse a cell’s biological age without erasing its identity — rather than clearing senescent cells outright.

The key directions of geroscience and senolytics are:

1. Senolytics: small molecules or peptides that selectively trigger apoptosis in senescent cells by disabling their survival pathways (SCAP networks), such as Bcl-2/Bcl-xL inhibition or FOXO4-p53 disruption.
2. Senomorphics: compounds — such as mTOR inhibitors (rapamycin analogs) and metformin — that don’t kill senescent cells but suppress their toxic SASP secretion.
3. Cellular rejuvenation: partial epigenetic reprogramming with Yamanaka factors to roll back a cell’s biological age while preserving its cell-type identity.
4. Senescence biomarking: biomarker platforms (SA-β-gal activity, single-cell RNA-seq, SASP cytokine panels) used to identify senescent cells and measure how effectively a therapy clears them.

Sectoral value chain

[Aging-Marker Identification] ──> [Senolytic Candidate Screening] ──> [Preclinical Testing (In Vivo)]
                  │                                 │                              │
        (SASP profiling, biomarkers)        (Compound libraries, HTS)    (Aged mouse models)
                                                                                    │
[Clinical Release (GMP)] <─── [Preclinical Synthesis & Purification (HPLC)] <──────┘

Value chain levels

Cross-cutting technologies of the sector:

• SA-β-gal detection: the classic senescent-cell biomarker — enlarged lysosomes in senescent cells sharply raise beta-galactosidase activity at pH 6.0, letting researchers quantify how well a therapy clears zombie cells from tissue.
• Bcl-2/Bcl-xL inhibition: drugs (e.g., navitoclax, UBX1325) that block the anti-apoptotic Bcl-2-family proteins senescent cells rely on for survival, pushing the cell into programmed apoptosis.
• FOXO4-DRI peptide design: a synthetic peptide that disrupts the FOXO4-p53 interaction in senescent cells, releasing p53 to trigger apoptosis while sparing healthy dividing cells.

02US

The US is the epicenter of the global longevity industry, combining a deep venture-capital ecosystem with pioneering academic geroscience centers.

senolytic clinical trials, cellular reprogramming megaprojects, academic senolytic discovery

• Unity Biotechnology: its lead senolytic, UBX1325 (a Bcl-xL inhibitor), has produced 36-week clinical results and a NEJM Evidence publication supporting long-term vision improvement in diabetic macular edema and retinal disease.
• Rubedo Life Sciences: develops selective senolytics using its AI-driven ALEMBIC platform; its lead candidate RLS-1496, a topical GPX4 modulator, reported positive preliminary Phase 1 results in plaque psoriasis, atopic dermatitis and skin aging.
• Altos Labs: launched around 2022 with roughly $3 billion in funding, pursuing partial cellular reprogramming for cellular rejuvenation rather than senescent-cell clearance.
• Mayo Clinic: ran a Phase 1 trial of the senolytic combination dasatinib plus quercetin (D+Q) in diabetic kidney disease, directly measuring reduced senescent-cell burden in treated patients.

03CN

China treats geroscience as a strategic response to rapid population aging and pension-system pressure, combining domestic senolytic discovery with dominance in a key longevity-supplement supply chain.

aging research in Beijing, NAD+ precursor manufacturing, domestic senolytic compound discovery

• Beijing research centers: the Institute of Zoology (Chinese Academy of Sciences) and Peking University are China’s leading aging-research centers, working on longevity-gene replacement approaches and natural senolytic compound discovery.
• NAD+ precursor manufacturing scale: China is the leading global producer and exporter of NAD+ coenzyme precursors such as nicotinamide mononucleotide (NMN), manufactured at large scale as a geroprotective supplement ingredient for export markets.
• Policy support: anti-aging research is incorporated into China’s national technology development programs, driving parallel investment in epigenetic-clock biological-age diagnostics.

04EU

The EU concentrates on fundamental geroscience and peptide-based senolytic discovery, operating under an EMA framework that does not recognize aging itself as an indication.

fundamental aging-pathway research, peptide senolytic design, EMA indication-specific regulation

• Max Planck Institute for Biology of Ageing (Cologne): a leading European academic hub studying molecular aging pathways (IIS, mTOR) in model organisms and coordinating geroprotector research across the EU.
• Cleara Biotech (Netherlands): founded in 2018, develops the FOXO4-DRI senolytic peptide, which disrupts the FOXO4-p53 interaction to selectively trigger apoptosis in senescent cells.
• EMA regulatory posture: EMA does not recognize biological aging as a standalone indication, so European senolytic developers must register their therapies against specific age-related diagnoses (e.g., idiopathic pulmonary fibrosis, osteoarthritis, sarcopenia) under existing disease codes.

05Leading companies and research institutes

06Tech stack and innovations

Modern geroprotector production and validation rests on the following technology stack:

1. Solid-phase peptide synthesis (SPPS):
   • Peptide senolytics like FOXO4-DRI are built stepwise on a solid resin using Fmoc-protected amino acids; substituting standard L-amino acids with mirror-image D-amino acids (retro-inverso peptides) makes them highly resistant to proteolytic degradation in blood.
2. Single-cell RNA sequencing (scRNA-seq):
   • Because senescent cells make up under roughly 1-5% of the total cell pool in aged tissue, bulk tissue sequencing can’t detect their signal; scRNA-seq profiles the RNA expression of thousands of individual cells to map specific SCAP-network and SASP-cytokine markers.
3. Ultra-high-performance liquid chromatography (UPLC-MS/MS):
   • Used to quantify SASP biomarkers (IL-6, IL-1, MCP-1 and related inflammatory proteins) in patient serum before and after senolytic therapy, assessing systemic anti-inflammatory and rejuvenating effect.

07Value chains and production pipelines

Industrial pipeline of GMP production for a peptide-type senolytic (FOXO4-DRI)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Solid-phase Fmoc       │ ───> │ 2. Cleavage from resin    │
│    synthesis (D-amino     │      │    with acid (TFA)         │
│    acids)                 │      │                            │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Membrane dialysis &    │ <─── │ 3. RP-HPLC chromatography │
│    desalting (TFF)        │      │    (substance purity)      │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Buffer formulation &   │ ───> │ 6. Sterile filtration &   │
│    SA-gal potency assay   │      │    aseptic fill-finish     │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Solid-phase peptide synthesis (SPPS)

A polymeric resin support (e.g., Rink amide resin) is loaded into an automated peptide synthesizer to build the FOXO4-DRI retro-inverso peptide from D-amino acid isomers, cycling through Fmoc deprotection, activation and coupling for each residue.

Stage 2: Cleavage from the polymeric support

Once the sequence is complete, the resin is washed and treated with a trifluoroacetic acid (TFA)/water/triisopropylsilane mixture, which cleaves the peptide from the resin and removes side-chain protecting groups; the crude peptide is precipitated in cold ether and dried.

Stage 3: Preparative RP-HPLC purification

The crude peptide is dissolved and loaded onto a C18 reverse-phase HPLC column, purified by an acetonitrile gradient, and collected at target purity (typically at least 98%) by UV detection.

Stage 4: Desalting and acetate-salt conversion

The eluate is processed by tangential-flow filtration (TFF) with a low-molecular-weight-cutoff membrane, exchanging residual TFA ions for physiological acetate ions via repeated diafiltration.

Stage 5: Formulation and potency testing

The purified peptide acetate is dissolved in sterile phosphate-buffered saline; identity and purity are confirmed by high-resolution mass spectrometry, and an in-vitro potency assay confirms selective apoptosis of senescent (SA-β-gal-positive) fibroblasts without harming healthy dividing controls.

Stage 6: Sterile filtration, fill and lyophilization

The formulated solution is sterile-filtered, filled into vials in a GMP Class A aseptic zone, lyophilized, sealed, labeled and stored under refrigeration ahead of clinical use.